NAD+

For licensed research and clinical evaluation only. Not dosing guidance.

Handling notes —Avoid repeated freeze–thaw cycles. Do not shake vigorously after reconstitution.

The following sources are representative of the literature describing NAD+. A full annotated citation list with PubMed identifiers is available on request.

1. Primary peer-reviewed publications indexed in PubMed describing mechanism, pharmacology, and preclinical activity.
2. Review articles summarizing the receptor pharmacology and translational research context for the compound class.
3. Public clinical-trials and regulatory databases (ClinicalTrials.gov, EMA, FDA Drugs@FDA) where applicable.
4. Manufacturer technical data sheets and independent third-party Certificates of Analysis on file.

See also the glossary of research terms and the full peptide library.

cGMP facility · Third-party tested · Cold-chain shipping · 24-hour COA on request